Comparing the current results to its competitors, Lexaria Bioscience reported Revenue decrease in the 3 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 125.67 %, recorded in the same quarter.
Lexaria Bioscience 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical industry, focusing on the development of API delivery platforms. It faces competition based on factors such as efficacy, safety, tolerability, reliability, convenience of use, price, and reimbursement. Competitors include major multinational pharmaceutical companies, established biotechnology firms, specialty pharmaceutical companies, universities, and research institutions, many of which possess greater financial and technical resources. These competitors may develop technologies comparable or superior to DehydraTECH.
Kaya Holdings Inc's business model revolves around operating and franchising legal cannabis retail stores under the Smoke Shop brand. Their focus is on offering a diverse range of cannabis products, accessories, and services to cater to the needs of consumers in states where marijuana is legalized.
Fsd Pharma Inc's business model is centered around the development and production of pharmaceutical-grade cannabis products. The company aims to leverage its in-house cultivation facility, research and development capabilities, and strategic partnerships to create innovative cannabis-based therapies for various medical conditions. Fsd Pharma focuses on pursuing licensing and acquisition opportunities to expand its presence in the global cannabis market.
The Greater Cannabis Company Inc Share Performance
-23.00%
Over The Past 5 Days
The Greater Cannabis Company Inc
Profile
The Greater Cannabis Company Inc's business model involves the cultivation, processing, and distribution of cannabis products. They aim to offer a wide range of cannabis-related goods to cater to the demands of both medical and recreational users.
Earth Science Tech Inc is a biotechnology company focused on developing and marketing innovative hemp cannabinoid-based products. Their business model revolves around research, development, manufacturing, and distribution of high-quality CBD and nutraceuticals for various industries, including the pharmaceutical and nutrition sectors.
Cv Sciences Inc operates through a business model focused on the production and sale of cannabidiol (CBD) based products. The company sources hemp for extraction, processes it into various CBD products, and distributes them through multiple channels, including online sales and retail partnerships. By leveraging the growing demand for CBD, Cv Sciences Inc aims to generate revenue and establish a market presence in the emerging health and wellness industry.
Sources:
Lexaria Bioscience Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lexaria Bioscience Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
